Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of “Buy” by Analysts
Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of “Buy” by Analysts Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) have been given a consensus rating of “Buy” by the nineteen research firms that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating and twelve have given a buy rating […]
Read More